Judah Frommer
Stock Analyst at Morgan Stanley
(4.05)
# 539
Out of 5,093 analysts
184
Total ratings
61.03%
Success rate
8.44%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVMN Evommune | Initiates: Overweight | $36 | $17.84 | +101.79% | 1 | Dec 1, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Overweight | $18 → $19 | $12.98 | +46.38% | 2 | Nov 14, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $34 → $37 | $38.28 | -3.34% | 1 | Nov 13, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $71 → $101 | $123.04 | -17.91% | 3 | Sep 12, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Equal-Weight | $25 → $26 | $23.78 | +9.34% | 2 | Jul 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Overweight | $46 → $43 | $28.09 | +53.08% | 2 | May 9, 2025 | |
| RGNX REGENXBIO | Maintains: Overweight | $22 → $24 | $12.72 | +88.68% | 2 | Mar 14, 2025 | |
| GLPG Galapagos NV | Downgrades: Underweight | $31 → $22 | $31.63 | -30.45% | 3 | Feb 14, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Underweight | $8 → $6 | $10.51 | -42.91% | 2 | Jan 13, 2025 | |
| ACLX Arcellx | Maintains: Overweight | $81 → $106 | $70.84 | +49.63% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $18.72 | +86.97% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $3 | $2.21 | +35.75% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $1.77 | +2,159.89% | 8 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $1.95 | +566.67% | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $71.30 | -57.92% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $30.47 | -24.52% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $73.47 | -31.95% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $22.17 | +535.99% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $4.39 | +105.01% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $34.80 | -36.78% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $5.66 | +23.67% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $14.60 | -45.21% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $88.89 | -48.25% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $3.79 | +84.70% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $20.78 | +164.68% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $194.17 | -76.31% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $93.75 | -47.73% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $888.44 | -58.35% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $75.36 | -58.86% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $72.59 | +4.70% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $125.54 | +44.97% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $119.68 | -10.59% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $114.07 | -16.72% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $17.23 | +4.47% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $175.34 | -33.84% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $90.36 | -57.95% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $83.24 | -73.57% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $62.90 | -44.36% | 9 | Apr 29, 2020 |
Evommune
Dec 1, 2025
Initiates: Overweight
Price Target: $36
Current: $17.84
Upside: +101.79%
Trevi Therapeutics
Nov 14, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $12.98
Upside: +46.38%
Zenas BioPharma
Nov 13, 2025
Maintains: Overweight
Price Target: $34 → $37
Current: $38.28
Upside: -3.34%
ABIVAX Société Anonyme
Sep 12, 2025
Maintains: Overweight
Price Target: $71 → $101
Current: $123.04
Upside: -17.91%
Apellis Pharmaceuticals
Jul 2, 2025
Maintains: Equal-Weight
Price Target: $25 → $26
Current: $23.78
Upside: +9.34%
Celldex Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $46 → $43
Current: $28.09
Upside: +53.08%
REGENXBIO
Mar 14, 2025
Maintains: Overweight
Price Target: $22 → $24
Current: $12.72
Upside: +88.68%
Galapagos NV
Feb 14, 2025
Downgrades: Underweight
Price Target: $31 → $22
Current: $31.63
Upside: -30.45%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Underweight
Price Target: $8 → $6
Current: $10.51
Upside: -42.91%
Arcellx
Nov 6, 2024
Maintains: Overweight
Price Target: $81 → $106
Current: $70.84
Upside: +49.63%
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $18.72
Upside: +86.97%
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $2.21
Upside: +35.75%
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $1.77
Upside: +2,159.89%
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $1.95
Upside: +566.67%
Aug 9, 2023
Reiterates: Outperform
Price Target: $30
Current: $71.30
Upside: -57.92%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $30.47
Upside: -24.52%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $73.47
Upside: -31.95%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $22.17
Upside: +535.99%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $4.39
Upside: +105.01%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $34.80
Upside: -36.78%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $5.66
Upside: +23.67%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $14.60
Upside: -45.21%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $88.89
Upside: -48.25%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $3.79
Upside: +84.70%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $20.78
Upside: +164.68%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $194.17
Upside: -76.31%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $93.75
Upside: -47.73%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $888.44
Upside: -58.35%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $75.36
Upside: -58.86%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $72.59
Upside: +4.70%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $125.54
Upside: +44.97%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $119.68
Upside: -10.59%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $114.07
Upside: -16.72%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $17.23
Upside: +4.47%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $175.34
Upside: -33.84%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $90.36
Upside: -57.95%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $83.24
Upside: -73.57%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $62.90
Upside: -44.36%